we are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. our area of expertise is in disorders of paradoxical mineralization and our lead drug is an enzyme replacement therapy in pre-clinical development.
Company profile
Ticker
INZY
Exchange
Website
CEO
Axel Bolte
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Inozyme Pharma, LLC
SEC CIK
Corporate docs
Subsidiaries
Inozyme Securities Corp. • Inozyme Pharma Ireland Limited • Inozyme Pharma Switzerland GmbH ...
IRS number
475129768
INZY stock data
Latest filings (excl ownership)
8-K
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
8 Apr 24
S-8
Registration of securities for employees
12 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
12 Mar 24
EFFECT
Notice of effectiveness
16 Nov 23
CORRESP
Correspondence with SEC
13 Nov 23
UPLOAD
Letter from SEC
10 Nov 23
S-3
Shelf registration
7 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
7 Nov 23
Latest ownership filings
4
Douglas A Treco
3 Apr 24
4
Matthew Winton
3 Apr 24
4
Matthew Winton
15 Mar 24
4
Douglas A Treco
15 Mar 24
4
Sanjay Subramanian
15 Mar 24
SC 13D/A
Sofinnova Venture Partners X, L.P.
20 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
New Enterprise Associates 15, L.P.
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 47.21 mm | 47.21 mm | 47.21 mm | 47.21 mm | 47.21 mm | 47.21 mm |
Cash burn (monthly) | (no burn) | (no burn) | 6.02 mm | 6.03 mm | 6.29 mm | 5.55 mm |
Cash used (since last report) | n/a | n/a | 41.15 mm | 41.19 mm | 42.95 mm | 37.90 mm |
Cash remaining | n/a | n/a | 6.06 mm | 6.02 mm | 4.25 mm | 9.31 mm |
Runway (months of cash) | n/a | n/a | 1.0 | 1.0 | 0.7 | 1.7 |
Institutional ownership, Q2 2023
81.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 78 |
Opened positions | 33 |
Closed positions | 8 |
Increased positions | 25 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 187.03 bn |
Total shares | 50.30 mm |
Total puts | 46.60 k |
Total calls | 17.60 k |
Total put/call ratio | 2.6 |
Largest owners | Shares | Value |
---|---|---|
Adage Capital Partners GP, L.L.C. | 4.25 mm | $23.67 bn |
Longitude Capital Partners III | 4.17 mm | $18.70 mm |
Venrock Healthcare Capital Partners II | 3.87 mm | $0.00 |
Pivotal bioVenture Partners Fund I | 3.66 mm | $22.26 mm |
Pivotal bioVenture Partners Investment Advisor | 3.66 mm | $20.39 bn |
Sofinnova Investments | 3.66 mm | $20.36 bn |
Rock Springs Capital Management | 3.43 mm | $19.09 bn |
NEA Management | 2.44 mm | $13.58 bn |
New Enterprise Associates 15 | 2.44 mm | $16.63 mm |
Millennium Management | 2.21 mm | $12.29 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Treco Douglas A | Common Stock | Sell | Dispose S | No | No | 6.94 | 7,523 | 52.21 k | 20,665 |
1 Apr 24 | Treco Douglas A | Common Stock | Option exercise | Acquire M | No | No | 0 | 25,000 | 0.00 | 28,188 |
1 Apr 24 | Treco Douglas A | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 25,000 | 0.00 | 75,000 |
28 Mar 24 | Matthew Winton | Common Stock | Grant | Acquire A | No | No | 3.33 | 3,188 | 10.62 k | 3,188 |
13 Mar 24 | Matthew Winton | Stock Option Common Stock | Grant | Acquire A | No | No | 5.77 | 175,000 | 1.01 mm | 175,000 |
13 Mar 24 | Treco Douglas A | Stock Option Common Stock | Grant | Acquire A | No | No | 5.77 | 300,000 | 1.73 mm | 300,000 |
13 Mar 24 | Subramanian Sanjay | Stock Option Common Stock | Grant | Acquire A | No | No | 5.77 | 165,000 | 952.05 k | 165,000 |
News
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
10 Apr 24
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
9 Apr 24
B of A Securities Maintains Buy on Inozyme Pharma, Lowers Price Target to $14
9 Apr 24
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
9 Apr 24
Inozyme Pharma Announces Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
8 Apr 24
Press releases
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
8 Apr 24
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Apr 24
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
26 Mar 24
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
12 Mar 24